Conclusions Using smart insoles we were able to quantify gait speed and stride variability. The potential value of smart-insoles is the portability of the technology that would enable their use outside of specialist gait clinics and potentially to monitor gait change in the individual’s home or residential care setting. These devices generate vast quantities of data leading to the possibility of using machine learning and data analytics platforms to identify new clinical sensitive signals within the data set. It was outside the scope of this pilot to determine the minimal clinically important differences (MCID) for cognitive decline; this would require a significant body of research. In addition is should be noted that factors such as footwear and data transfer could impact the operationalization of these devices in clinical trial and needs careful consideration before implementation in a clinical trial.